HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: db08-0138v1 57/9/2341    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Monti, P. Articles by Battaglia, M. PubMed PubMed Citation Articles by Monti, P. Articles by Battaglia, M. Social Bookmarking                What's this?

Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4⁺CD25⁺FOXP3⁺ Regulatory T-Cells

¹ Telethon-Juvenile Diabetes Research Foundation Center for Beta Cell Replacement, San Raffaele Scientific Institute, Milan, Italy
² Department of Medicine, Transplant Unit, San Raffaele Scientific Institute, Milan, Italy
³ San Raffaele Telethon Institute for Gene Therapy, Milan, Italy
⁴ Università Vita-Salute San Raffaele, Milan, Italy
⁵ San Raffaele Scientific Institute, Immunology of Diabetes Unit, Milan, Italy

Corresponding author: Manuela Battaglia, manuela.battaglia{at}hsr.it

OBJECTIVE—Rapamycin is an immunosuppressive drug currently used to prevent graft rejection in humans, which is considered permissive for tolerance induction. Rapamycin allows expansion of both murine and human naturally occurring CD4⁺CD25⁺FOXP3⁺ T regulatory cells (nTregs), which are pivotal for the induction and maintenance of peripheral tolerance. Preclinical murine models have shown that rapamycin enhances nTreg proliferation and regulatory function also in vivo. Objective of this study was to assess whether rapamycin has in vivo effects on human nTregs.

RESEARCH DESIGN AND METHODS—nTreg numbers and function were examined in a unique set of patients with type 1 diabetes who underwent rapamycin monotherapy before islet transplantation.

RESULTS—We found that rapamycin monotherapy did not alter the frequency and functional features, namely proliferation and cytokine production, of circulating nTregs. However, nTregs isolated from type 1 diabetic patients under rapamycin treatment had an increased capability to suppress proliferation of CD4⁺CD25^– effector T-cells compared with that before treatment.

CONCLUSIONS—These findings demonstrate that rapamycin directly affects human nTreg function in vivo, which consists of refitting their suppressive activity, whereas it does not directly change effector T-cell function.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?